Drug
Esaxerenone clinical trials
Also written CS-3150.
- studies test it
- 11
- open now
- 0
- in phase 3
- 5
- first study started
- 2015
How studies write it
Studies that test it under each name
Name
Development codes
- CS-3150
- 11
Studies by the year they started
11 studies that test it; most in 2016 (7)
| Year | Studies |
|---|---|
| 2015 | 4 |
| 2016 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 5
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses esaxerenone is read from its arms, and is right about nine times in ten.
Testing it · 11
- Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential HypertensionCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02722265Written as CS-3150
- A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive SubjectsCompletedPhase 2Daiichi SankyoNCT02345044Written as CS-3150
- A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal ImpairmentCompletedPhase 2Daiichi SankyoNCT02448628Written as CS-3150
- The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy VolunteersCompletedPhase 1Daiichi SankyoNCT04019652Written as CS-3150
- Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and AlbuminuriaCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02807974Written as CS-3150
- Study of CS-3150 in Patients With Primary AldosteronismCompletedNot applicableDaiichi Sankyo Co., Ltd.NCT02885662Written as CS-3150
- Study of CS-3150 in Patients With Essential HypertensionCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02890173Written as CS-3150
- A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With MicroalbuminuriaCompletedPhase 2Daiichi SankyoNCT02345057Written as CS-3150
- Study of CS-3150 in Patients With Severe HypertensionCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02808026Written as CS-3150
- Study of CS-3150 Compared to Olmesartan in Patients With Essential HypertensionCompletedNot applicableDaiichi Sankyo Co., Ltd.NCT02848170Written as CS-3150
- Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal ImpairmentCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02807987Written as CS-3150
Codes
What other systems call esaxerenone · ClinicalTrials.gg INT000456
- MeSH (NLM) C000607547esaxerenoneOne source NLM
- UNII (FDA) N62TGJ04A1ESAXERENONEConfirmed FDA, NLM, Wikidata
- Wikidata Q27284603esaxerenoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174741EsaxerenoneOne source FDA
- DrugBank DB15207One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000607547 | esaxerenone | One source NLM |
| UNII (FDA) | N62TGJ04A1 | ESAXERENONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27284603 | esaxerenone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174741 | Esaxerenone | One source FDA |
| DrugBank | DB15207 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.